Corneal graft rejection is a severe complication that can follow penetrating keratoplasty (PKP), possibly leading to severe endothelial cell loss and corneal decompensation. [1,2] Risk factors for ...

Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

Cellusion has received FDA orphan drug designation for its iPSC-derived corneal endothelial cell substitutes for the treatment of bullous keratopathy, and an exploratory clinical study has been ...